Aim: To measure, by a quantitative approach, the gene expression underlying the results of somatostatin receptor (sst) scintigraphy (111In-DTPA-octreotide) and noradrenaline transporter (NAT) scintigraphy (123I-MIBG) in patients with neuroendocrine (NE) tumors. Methods: The gene expression of somatostatin receptors 1–5 (sst) and NAT was measured quantitatively by real-time PCR in a group of patients with NE tumors (n = 14) and compared to a group of patients with colorectal adenocarcinomas (n = 15). If available, scintigraphic results were compared with gene expression results (9 octreotide and 3 MIBG scintigraphies). Results: The sst2 was upregulated in 13 of 14 patients (93%) with NE tumors, and the absolute level of gene expression was highest for sst2. Gene expression alterations of NAT and the other sst subtypes were more variable. Gene expression of sst2 was in all cases in agreement with positive octreotide scintigraphies. In 2 of 3 cases where MIBG scintigraphy was positive, NAT was also upregulated. Sst2 was generally downregulated in the colorectal tumor group with the gene expression of the other receptors being more heterogeneous. Conclusions: In general, changes in gene expression of sst2 corresponded with scintigraphic results. Our data support that sst2 is the best target for visualization of NE tumors, whereas NAT is only a useful target in a subpopulation of NE tumors. Comparison of scintigraphic results with quantitative gene expression may be used to achieve a better understanding of the link between them, which in turn could aid in planning and development of noninvasive molecular imaging of key molecular processes.

1.
Schnirer II, Yao JC, Ajani JA: Carcinoid – a comprehensive review. Acta Oncol 2003;42:672–692.
2.
Moertel CG, Engström PF, Schutt AJ: Tamoxifen therapy for metastatic carcinoid tumor: a negative study. Ann Intern Med 1984;100:531–532.
3.
Kaltsas GA, Besser GM, Grossman AB: The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004;25:458–511.
4.
Solcia E, Rindi G, Paolotti D, La RS, Capella C, Fiocca R: Clinicopathological profile as a basis for classification of the endocrine tumours of the gastroenteropancreatic tract. Ann Oncol 1999;10(suppl 2):S9–S15.
5.
Reubi JC: Somatostatin and other peptide receptors as tools for tumor diagnosis and treatment. Neuroendocrinology 2004;80 (suppl 1):51–56.
6.
Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB: The somatostatin receptor family. Life Sci 1995;57:1249–1265.
7.
Reubi JC, Waser B, Schaer JC, Laissue JA: Somatostatin receptor sst1–sst5 expression in normal and neoplastic human tissues using receptor autoradiography with subtype-selective ligands. Eur J Nucl Med 2001;28:836–846.
8.
Reubi JC, Schaer JC, Waser B, Mengod G: Expression and localization of somatostatin receptor SSTR1, SSTR2, and SSTR3 messenger RNAs in primary human tumors using in situ hybridization. Cancer Res 1994;54:3455–3459.
9.
Papotti M, Croce S, Macri L, Funaro A, Pecchioni C, Schindler M, et al: Correlative immunohistochemical and reverse transcriptase polymerase chain reaction analysis of somatostatin receptor type 2 in neuroendocrine tumors of the lung. Diagn Mol Pathol 2000;9:47–57.
10.
Casini Raggi C, Calabrò A, Renzi D, Briganti V, Cianchi F, Messerini L, et al: Quantitative evaluation of somatostatin receptor subtype 2 expression in sporadic colorectal tumor and in the corresponding normal mucosa. Clin Cancer Res 2002;8:419–427.
11.
Buscail L, Saint-Laurent N, Chastre E, Vaillant JC, Gespach C, Capella G, et al: Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res 1996;56:1823–1827.
12.
Krenning EP, Kwekkeboom DJ, Oei HY, Reubi JC, van Hagen PM, Kooij PP, et al: Somatostatin receptor imaging of endocrine gastrointestinal tumors. Schweiz Med Wochenschr 1992;122:634–637.
13.
Kaltsas G, Korbonits M, Heintz E, Mukherjee JJ, Jenkins PJ, Chew SL, et al: Comparison of somatostatin analog and meta-iodobenzylguanidine radionuclides in the diagnosis and localization of advanced neuroendocrine tumors. J Clin Endocrinol Metab 2001;86:895–902.
14.
Plockinger U, Rindi G, Arnold R, Eriksson B, Krenning EP, de Herder WW, et al: Guidelines for the diagnosis and treatment of neuroendocrine gastrointestinal tumours. A consensus statement on behalf of the European Neuroendocrine Tumour Society (ENETS). Neuroendocrinology 2004;80:394–424.
15.
Hopfner M, Sutter AP, Beck NI, Barthel B, Maaser K, Jockers-Scherubl MC, et al: Meta-iodobenzylguanidine induces growth inhibition and apoptosis of neuroendocrine gastrointestinal tumor cells. Int J Cancer 2002;101:210–216.
16.
Altmann A, Kissel M, Zitzmann S, Kübler W, Mahmut M, Peschke P, et al: Increased MIBG uptake after transfer of the human norepinephrine transporter gene in rat hepatoma. J Nucl Med 2003;44:973–980.
17.
Carlin S, Mairs RJ, McCluskey AG, Tweddle DA, Sprigg A, Estlin C, et al: Development of a real-time polymerase chain reaction assay for prediction of the uptake of meta-[131I]iodobenzylguanidine by neuroblastoma tumors. Clin Cancer Res 2003;9:3338–3344.
18.
Lode HN, Bruchelt G, Seitz G, Gebhardt S, Gekeler V, Niethammer D, et al: Reverse transcriptase-polymerase chain reaction (RT-PCR) analysis of monoamine transporters in neuroblastoma cell lines: correlations to meta-iodobenzylguanidine (MIBG) uptake and tyrosine hydroxylase gene expression. Eur J Cancer 1995;31A:586–590.
19.
Kolby L, Bernhardt P, Levin-Jakobsen AM, Johanson V, Wangberg B, Ahlman H, et al: Uptake of meta-iodobenzylguanidine in neuroendocrine tumours is mediated by vesicular monoamine transporters. Br J Cancer 2003;89:1383–1388.
20.
Kolby L, Bernhardt P, Johanson V, Wangberg B, Muth A, Jansson S, et al: Can quantification of VMAT and SSTR expression be helpful for planning radionuclide therapy of malignant pheochromocytomas? Ann N Y Acad Sci 2006;1073:491–497.
21.
Hoefnagel CA, Voûte PA, de Kraker J, Marcuse HR: Radionuclide diagnosis and therapy of neural crest tumors using iodine-131 metaiodobenzylguanidine. J Nucl Med 1987;28:308–314.
22.
Rappeport ED, Hansen CP, Kjaer A, Knigge U: Multidetector computed tomography and neuroendocrine pancreaticoduodenal tumors. Acta Radiol 2006;47:248–256.
23.
Vandesompele J, De Preter K, Pattyn F, Poppe B, Van Roy N, De Paepe A, et al: Accurate normalization of real-time quantitative RT-PCR data by geometric averaging of multiple internal control genes. Genome Biol 2002;3:RESEARCH0034.
24.
Pfaffl MW: A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res 2001;29:e45.
25.
Reubi JC, Schär JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al: Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27:273–282.
26.
Patel YC, Srikant CB: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1–5). Endocrinology 1994;135:2814–2817.
27.
Papotti M, Croce S, Bello M, Bongiovanni M, Allia E, Schindler M, et al: Expression of somatostatin receptor types 2, 3 and 5 in biopsies and surgical specimens of human lung tumours. Correlation with preoperative octreotide scintigraphy. Virchows Arch 2001;439:787–797.
28.
Rochaix P, Delesque N, Estève JP, Saint-Laurent N, Voight JJ, Vaysse N, et al: Gene therapy for pancreatic carcinoma: local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum Gene Ther 1999;10:995–1008.
29.
Butturini G, Bettini R, Missiaglia E, Mantovani W, Dalai I, Capelli P, et al: Predictive factors of efficacy of the somatostatin analogue octreotide as first-line therapy for advanced pancreatic endocrine carcinoma. Endocr Relat Cancer 2006;13:1213–1221.
30.
Mundschenk J, Unger N, Schulz S, Hollt V, Schulz S, Steinke R, et al: Somatostatin receptor subtypes in human pheochromocytoma: subcellular expression pattern and functional relevance for octreotide scintigraphy. J Clin Endocrinol Metab 2003;88:5150–5157.
31.
Jais P, Terris B, Ruszniewski P, LeRomancer M, Reyl-Desmars F, Vissuzaine C, et al: Somatostatin receptor subtype gene expression in human endocrine gastroentero-pancreatic tumours. Eur J Clin Invest 1997;27:639–644.
32.
Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al: Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439–1447.
33.
Beutler D, Avoledo P, Reubi JC, Mäcke HR, Müller-Brand J, Merlo A, et al: Three-year recurrence-free survival in a patient with recurrent medulloblastoma after resection, high-dose chemotherapy, and intrathecal yttrium-90-labeled DOTA0-D-Phe1-Tyr3-octreotide radiopeptide brachytherapy. Cancer 2005;103:869–873.
34.
Kwekkeboom DJ, Mueller-Brand J, Paganelli G, Anthony LB, Pauwels S, Kvols LK, et al: Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46 (suppl 1):62S–66S.
35.
Kwekkeboom DJ, Teunissen JJ, Bakker WH, Kooij PP, de Herder WW, Feelders RA, et al: Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors. J Clin Oncol 2005;23:2754–2762.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.